|D012127||Respiratory Distress Syndrome, Newborn NIH||0.08|
|D055371||Acute Lung Injury NIH||0.08|
|D012128||Respiratory Distress Syndrome, Adult NIH||0.07|
There is one clinical trial.
This study aims to evaluate the safety and immunogenicity of the preventative vaccine, AdimrSC-2f, in healthy volunteers aged from 20 to 60 years old.
Description: Determining the solicited adverse events (SoAEs) (the percentage, severity, and relationship to the AdimrSC-2f vaccine) during 7 days following each vaccination.Measure: The solicited adverse events (SoAEs) Time: The 7 days following each vaccination
Description: Determining the clinically significant changes in hematology, biochemistry, and coagulation results from baseline at Visit 2 and Visit 4.Measure: Incidence of abnormal laboratory tests results Time: Day 7 after vaccination
Description: Determining the SoAEs and unsolicited AES (the percentage, severity, and relationship to AdimrSC-2f vaccine) during the study period. Overall AEs and serious adverse events (SAEs) during the study period.Measure: Safety of AdimrSC-2f vaccine: AE Time: Day 0 to Day 182
Description: Determining the changes of antibody titers between baseline and the subsequent scheduled visitsMeasure: Immunogenicity Time: Day 7,21,28,and 42
Description: Determining the geometric mean increase (GMI)Measure: Immunogenicity Time: Day 21 and 42
Description: Determining the seroconversion rate (SCR)Measure: Immunogenicity Time: Day 21 and 42
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports